WO2018236206A1 - Composition dérivée de palmier à huile pour le traitement de la peau - Google Patents

Composition dérivée de palmier à huile pour le traitement de la peau Download PDF

Info

Publication number
WO2018236206A1
WO2018236206A1 PCT/MY2018/050037 MY2018050037W WO2018236206A1 WO 2018236206 A1 WO2018236206 A1 WO 2018236206A1 MY 2018050037 W MY2018050037 W MY 2018050037W WO 2018236206 A1 WO2018236206 A1 WO 2018236206A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic composition
oil
skin
composition
vitamin
Prior art date
Application number
PCT/MY2018/050037
Other languages
English (en)
Inventor
Oi Ming Lai
Mun Hoe NICHOLAS KHONG
Wee Ting LAI
Original Assignee
Universiti Putra Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Putra Malaysia filed Critical Universiti Putra Malaysia
Publication of WO2018236206A1 publication Critical patent/WO2018236206A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • compositions comprising nanonized palm-derived Vitamin E and Vitamin A or Vitamin C, which exhibit synergistic effects for use in therapeutic prevention or treatment of common skin disorders.
  • Eczema occurs in individuals of all races and ages. Eczema is an inflammatory skin condition, characterised by ichtyosis (dry skin), erythema (redness), excoriation (interruption of the skin), scratching lesions, lichenification (thickening of the skin), infected lesions (blisters, pus formation) and hypopigmentation in old lesions.
  • atopic eczema or endogenous eczema also known as atopic dermatitis.
  • AD affects up to 20% of children and up to 3% of adults worldwide; the incidence has increased by 2- to 3-folds during the past decades in industrialized countries and recent data show that its prevalence increasing more rapidly in low-income countries.
  • eczema There is no cure for eczema, but, in most cases, it is manageable and preventable.
  • clinical management of eczema involves therapeutic corticosteroids in reducing inflammation of the skin e.g. halcinonide 0.1 %, hydrocortisone butyrate 0.1 %, hydrocortisone valerate 0.2% and desonide 0.05%.
  • Potent corticosteroids also have anti Staphylococcus aureus properties and have immunosuppressive and vasoconstrictive properties.
  • corticosteroids have side effects such as skin thinning, skin irritation, skin discoloration, acne, easy bruising, fragile blood vessels and excessive hair growth. Corticosteroids of very high potency must be avoided in children. With the growth of consumer awareness nowadays, the demand for effective nonsteroidal alternatives for eczema managements are all time high.
  • Another invention presents a method for the treatment and protection of human and animal skin which contains vitamin E in a high dose and, in addition, may optionally further contain vitamin C, vitamin A, vitamins of the B series, blood circulation-promoting agents and/or vasodilators, phospholipids, unsaturated fatty acids and/or emulsifiers.
  • Vitamin E used, when Vitamin E in the industry commonly refers to tocopherol (T1 ).
  • the composition also involves the addition of pharmaceutical drugs specifically antihistaminic drugs and Bufexamac, and anti-inflammatory drug.
  • US 2002/0120001 A1 discloses a formulation of tryptamine, mixed tocotrienols and carotenoids that synergistically inhibits the generation of free radicals and oxidative stress.
  • melatonin which is used as the tryptamine of the formulation is a type of hormone that is possible unsafe for children application. Because of its effects on other hormones, melatonin might interfere with development during adolescence.
  • the carotenoids used specifically astaxanthin, beta-carotene, lutein and lycopene, lack stability (easily oxidized) and are synthetic compounds. The invention does not specify its application for the treatment and prevention of skin disorders.
  • US 2004/0241254 A1 discloses a cosmeceutical formulation which includes a votated blend of different palm oils to treat a variety of skin conditions or as an effective moisturizer. However, the formula is substantially water free and might not present desirable rheological properties. Similarly, US 2005/0100524 A1 also discloses a combination of oils, majorly from shea butter, mango butter, cocoa butter, jojoba and coconut.
  • nanonization technology to bioactive deliveries are desirable for enhanced and stable bioavailability, resulting in higher therapeutic penetration of bioactives and stability of oil-in-water (O/W) or water-in-oil (W/O) compositions.
  • O/W oil-in-water
  • W/O water-in-oil
  • dosage of effective bioactive concentration necessary would decrease leading higher cost effectiveness.
  • nanotechnology plays an important role in cosmeceuticals, concerns have been raised regarding the potential dangers that may occur when nanoparticles penetrate the skin.
  • nanonized formulations for the treatment of inflammation
  • US 2007/0036831 A1 describes an antimicrobial nanoemulsion composition containing an aqueous phase, an oil phase comprising an oil and an organic solvent, at least one anti-inflammatory agent, and one or more surfactants.
  • the composition involves the addition of steroidal drugs or nonsteroidal anti-inflammatory drugs (NSAIDS) that possibly causes undesirable side effects.
  • NSAIDS nonsteroidal anti-inflammatory drugs
  • Another embodiment (US 2014/0348938 A1 ) prepares solid lipid sustained release nanoparticles for delivery of drugs/vitamins, more specifically Vitamin D 3 and retinoic acid (RA) involving microemulsion technique for the treatment of age related macular degeneration, diabetic retinopathy, cancers, hyperpigmentation, acne, and osteoporosis.
  • This invention mixes pure vitamin compounds and does not specify usage for dermatitis.
  • US 8197851 B2 describes a carotenoids composition in an oil medium with size smaller than 100 nm that can be used in the sunscreen, moisturiser and other skin care products for the treatment of eczema and psoriasis.
  • the composition only uses carotenoids, more specifically from the microalgae Dunaliella salina, which is not a major source of carotenoids.
  • a therapeutic composition comprising nanonized palm oil or actives derived from combination of at least one member selected from Group A consisting of Vitamin A and pro-vitamin A; at least one member selected from Group E consisting of Vitamin E and pro-vitamin E; and at least one member selected from a Group C consisting of Vitamin C and pro-vitamin C.
  • the nanonized composition having average particle sizes below 350 nm, is combined with a topical cosmetic, pharmaceutical, medical or micronized or nanonized base in about 0.1 to 30% (w/w) forming a therapeutic formulation.
  • the therapeutic formulation includes liquid, semi aqueous, cream, serum, gel, oilment, lotion, spray, balm and mist.
  • It is accordingly an object of the present invention to provide the use of a therapeutic composition comprising nanonized palm oil or actives derived from combination of at least one member selected from group consisting of Vitamin A and pro-vitamin A; at least one member selected from group consisting of Vitamin E and pro-vitamin E; and at least one member selected from group consisting of Vitamin C and pro-vitamin C as anti-inflammatory, anti-microbial, anti-pruritic, wound healing and skin hydration to prevent or treat eczema or psoriasis.
  • the use of the said therapeutic composition topically, in any cosmetic or pharmaceutical base or carrier by liquid, semi aqueous, cream, serum, gel, oilment, lotion, spray, balm and mist, is applied together with a composition comprising oil, solid fat and actives capable of occlusive and humectant moisturizing properties.
  • a composition comprising oil, solid fat and actives capable of occlusive and humectant moisturizing properties.
  • the use of therapeutic composition is anti-inflammatory, anti-microbial, anti-pruritic, wound healing and skin hydration to prevent or treat eczema or psoriasis.
  • It is another object of the present invention to provide a therapeutically effective cream formulation comprises at least 60% w/w water, between 0.1 -5% w/w gelling agent and/or thickener, between 1 -5% w/w active ingredient and/or plant extracts, between 1 -5% w/w solubilizer, between 1 -5% w/w emulsifier, between 1 -5% w/w moisturizer, between 1 -10% w/w humectant, between 1 -15% w/w emollient, between 0.1 -2% w/w chelating agent, between 0.1 -2% w/w preservatives and emulsion at 1 -10% w/w for treatment or prevention of skin with dry or pruritic or inflammatory condition.
  • Figure 1 shows a comparison of nanonized formulation with micronized formulation and oil only in penetration of nutrients, average particle size, stability and inhibition of eczema-causing pathogen, Staphylococcus aureus.
  • Figure 2 shows marked improvements of psoriasis condition in a 26 years old female with dry skin and skin interruptions (excoriations) upon 10 days of topical application.
  • Figure 3 shows improvement of itchiness and dryness conditions upon 7 days of topical application.
  • Figure 4 shows improvement of all eczema symptoms after 14 days of topical application.
  • Figure 5 shows improvements of severe eczema in a 48 years old male, localized on both legs (between knee and ankle region) since 2005 that led to severe skin interruption.
  • Cosmeceuticals are usually topically applied products that have physiological effects on the skin, simply put: a product that fits the niche between a pharmaceutical drug and cosmetics.
  • Nanobiotechnology is increasingly applied in cosmeceuticals, being the root of numerous innovations, as matter is manipulated at an atomic or molecular level. Manipulation of average particle size of active materials could attributes different functional and application properties for the purposeful design of new cosmeceuticals.
  • Formulations intervened by such manipulations provide new delivery system for cosmeceuticals, as hypotheticaily, smaller particles can enter and penetrate the skin better for increased active delivery or adsorption.
  • particle size manipulations includes micro or nanoformulations in forms of emulsion, capsule, pigment, crystal, multiple- layer particles, solid lipid particles, liposomes, niosomes, cubosomes, tranferosomes, carbon nanotubes, fullerene, dendrimers, graphene and quantum dots.
  • Nanoemulsion technology particularly, when used as a cosmetics and topical preparations has a great advantage over the other dosage forms that the formulation can be delivered by various routes including oral, ocular and transdermal.
  • Nanoemulsions consist of fine oil-in-water dispersions, having droplets covering the size range of below 600 nm. The smaller droplet size of emulsions not only suppresses the coalescence or coagulation of emulsion droplets but also suppresses the precipitation of emulsions and also helps to deliver the active agents.
  • Nanoemulsions usually spherical, are a group of dispersed particles used as delivery vehicles.
  • Nanoemulsion is a heterogeneous mixture of lipid and aqueous phase and stability are achieved by using a suitable material known as emulsifying agents. Nanoemulsion is a translucent system compare to ordinary emulsion or microemulsion. Oil in water type (O/W) of nanoemulsion formulation is prepared since long ago while water in oil (W/O) type of nanoemulsion is recently gaining popularity. Both of this type of nanoemulsion have various pro and cons in applications of food, pharmaceuticals and cosmetics.
  • O/W Oil in water type
  • W/O water in oil
  • nanoemulsion as a delivery system retention time of a drug in the body can be increased, so low amount of drug is required for the therapeutic action.
  • Utilization of nanoemulsion technology is able to enhance bioavailability of lipophilic drug.
  • the basic objectives of the nanoemulsion preparation are to achieve the droplet size range below 600 nm as well as to provide stability to the emulsion formed. Formation of a nanoemulsion system can be achieved either by manipulating mechanical equipment or the chemical potential inherent within the component. Some common methods include phase inversion, sonication and high pressure homogenization. Using the phase inversion method, fine dispersion is obtained by chemical energy resulting of phase transitions taking place through emulsification path.
  • Adequate phase transitions are produced by varying the composition of emulsion at constant temperature or by varying the temperature at constant emulsion composition.
  • surfactant becomes lipophilic with increase in temperature due to dehydration of polymer chain. But at low temperature, the surfactant monolayer has a large positive spontaneous curvature forming oil-swollen micellar solution phase.
  • Sonication method is another best way to prepare nanoemulsion. In this method the droplet size of conventional emulsion or even microemulsion are reduced with the help of sonication mechanism. However, this method is not suitable for large batches, only small batches of nanoemulsion can be prepared by this method.
  • High pressure homogenization is performed by applying a high pressure over the system having oil phase, aqueous phase and surfactant or co-surfactant.
  • the pressure is applied with the help of a special equipment know as homogenizer.
  • homogenizer There are some problems which are associated with homogenizer such as poor productivity, component deterioration due to difficult mass production and generation of much heat.
  • HPH only oil in water (07W) liquid nanoemulsion of less than 20% oil phase can be prepared and cream nanoemulsion of high viscosity or hardness with a mean droplet diameter lower than 200 nm cannot be prepared.
  • nanoformulations provide great advantages as a delivery system for bioactives but sometimes the reduced size of droplets are responsible for the limited use of nanoemulsion formulation.
  • One limitation of nanoemulsion is the production cost as the manufacturing of nanoemulsion formulation is an expensive and energy consuming process. Size reduction of droplets is very difficult as it required a special kind of instruments and process methods. For example, homogenizer (instrument required for the nanoemulsion formulation) arrangement is an expensive process. Again microfludization and ultrasonication require high amount of financial support.
  • stability of nanoemulsion mostly requires plenty of study and optimization as non-stable emulsion creates big problem in the storage of formulation. Ostwald ripening is the main factor associated with unacceptability of nanoemulsion formulations.
  • nuclear factor ⁇ transcription factor promotes the production of proteinases such as collagenase, leading to skin destruction.
  • activation of nuclear factor ⁇ transcription factor also causes the production of inflammatory mediators including tumor necrosis factor- alpha, cytokines, chemokines and cell adhesion molecules.
  • inflammatory mediators including tumor necrosis factor- alpha, cytokines, chemokines and cell adhesion molecules.
  • arachidonic acid is also released and oxidised via cyclooxygenase or lipoxygenase pathway to form hydroxyeicosatetraeenoic acid, prostaglandins and leukotrienes, leading to free radical production and causing erythema and oedema to the skin. Production of free radical further provokes inflammation.
  • Histamine a substance that involved in the inflammatory response is also released to fight the pathogens, but it triggers pruritic.
  • the described skin disorders intended to include in the present invention are eczema or psoriasis of all stages.
  • the types of eczema including atopic dermatitis, contact dermatitis, nummular dermatitis, seborrheic dermatitis, stasis dermatitis, neurodermatitis, hand eczema, dyshidrotic dermatitis, dermatitis herpetiforms or asteototic eczema.
  • the types of psoriasis including plaque psoriasis, pustular psoriasis, guttate psoriasis, erthrodermic psoriasis, arthropathic psoriasis, inverse psoriasis, psoriatic arthritis or nail psoriasis.
  • the present invention provides a formulation which when administered topically, is able to work synergistically for the prevention or treatment of skin disorders.
  • the therapeutic composition comprises nanonized phytonutrients of oil palm origin and vitamin C.
  • the oil palm based phytonutrients within the scope of this invention includes preferably oil rich in tocotrienols, tocopherols, carotenoids or their mixtures thereof, including crude palm oil, red palm oil or red palm olein.
  • the tocotrienol species includes alpha-, beta-, gamma-, and delta- tocotrienol and mixtures thereof.
  • the tocopherol species includes alpha-, beta-, gamma-, and delta-tocopherol and mixtures thereof.
  • the carotenoid species preferably includes beta-carotene, alpha-carotene, c/ ' s-alpha-carotene, c/ ' s-beta- carotene, lycopene, phytoene, beta-zeacarotenes, phytofluene, delta-carotene, gamma-carotene and mixtures thereof. Most preferably, the carotenoid species includes beta-carotene, alpha-carotene and mixture thereof.
  • composition of topical composition for prevention or treatment of eczema and psoriasis includes at least 0.1 % w/w of tocotrienols, at least 0.1 % w/w of tocopherols and at least 0.1 % w/w of carotenoids, which are derived from red palm olein, and at least 0.05% w/w of vitamin C, in nanonized formulation.
  • Vitamin E incorporates 8 different compounds. These include 4 tocopherols (alpha, beta, gamma and delta) and 4 tocotrienols (alpha, beta, gamma and delta). Vitamin E is an antioxidant and anti-inflammatory which is most abundant in human skin with alpha-tocopherol being the most predominant form. Naturally, bioaccumulation of vitamin E following oral administration in the epidermis could be achieved when sebaceous glands secrete vitamin E onto the skin and followed by skin penetration and accumulation. It was previously reported that, in order to alter the concentration of vitamin E in the skin through oral administration, it took at least seven days (Free Radic Biol Med 2004: 36(4):456-463).
  • Vitamin E labelled in many products usually refers to tocopherol or its analogues, unless specified otherwise.
  • Tocopherol molecules have a long tail with no double bonds. This inhibits the functional effects of the vitamin within the body. Hence, it has a much lower anti- oxidative capacity than its counterpart.
  • Tocotrienol molecules have a short tail with 3 double bonds. This unique structure enables the vitamin to perform various functions, especially antioxidative, with greater efficacy.
  • tocopherols and tocotrienols it was found that tocotrienols were found to be able to penetrate into the skin more efficiently and rapidly as compared to tocopherols.
  • Carotenoids are potent antioxidant that plays an essential role in the antioxidative protective system of human skin. It is well known with its ability to quench free radical species, serves to suppress inflammation. Among various types of carotenoids, non- polar carotenes and lycopene seem to be the predominant forms. Beta-carotene is one of the non-polar carotenes with provitamin A activity is found abundantly in red palm olein. Earlier study indicates that foods high in beta-carotene reduced the risk of developing psoriasis (Brit J Dermatol 1996: 134(1 ):101 -106). Beta-carotene regulated inflammation by functioning as an inhibitor for redox-based nuclear factor ⁇ transcription factor activation. In an animal study, it has been suggested that beta- carotene in combination with other carotenoids are effective in promoting wound healing (J Nutr 1982: 1 12(8) :1555-1564).
  • Vitamin C is a potent anti-inflammatory agent that mediates inflammation by inhibiting tumor necrosis factor alpha, which promotes nuclear factor ⁇ transcription factor activation. Suppression of nuclear factor ⁇ transcription factor activation reduces the proinflammatory cytokine production, suggesting that vitamin C is an appropriate agent for preventing and treating wide inflammatory conditions including skin inflammation, erythema and UV radiation damages.
  • administration of vitamin C in combination with vitamin E may work synergistically to improve the anti-inflammatory activity.
  • vitamin C in combination with vitamin E in a stabilised emulsion provided superior effect in improving the symptoms of skin disorder in comparison with single vitamin administration.
  • Topicals including cream, cold cream, ointment, gel, paste, semi-powder, liniment or lotion are semisolid dosage forms containing one or more actives or drug substances dissolved or dispersed in a suitable base.
  • a topical base is utmost important for the preparation of any cosmeceutical or cosmetic compositions, especially skin and body care as it determines the skin feel, smell, sometimes taste, and stability of the topical.
  • a topical aqueous cream comprises of extracts, emollient, humectant, moisturizer, surfactant, emulsifier, diluent and preservative.
  • the topical aqueous cream composition comprises emollient, which are biocompatible with the current invented composition and suitable for topical application.
  • emollient is substance with an occlusive property that is able to trap the natural moisture into the skin and prevent transepidermal moisture loss. They act by mimicking the role played by sebum. This skin hydrating effect helps to reduce scaling, fissuring, inflammation as well as pruritus, making the affected areas feel more comfortable. They also improve skin texture and preventing skin cracks.
  • the emollient useful in the topical composition includes isononyl isononanoate, dimethicone, dimethiconol, dimethicone crosspolymer, phenyl trimethicone, cetearyl alcohol, stearyl alcohol, lanolin, C12-15 alkyl benzoate or cyclopentasiloxane.
  • the topical aqueous cream composition comprises humectants, which are biocompatible with the current invented composition and suitable for topical application.
  • humectant is a compound which attracts water by mimicking the role of natural moisturising factor that present within the upper epidermis of the skin in nature, such as pyrrolidone carboxylic acid.
  • the humectant useful in the topical composition includes butylenes glycol, propylene glycol, glycerin or sodium hyaluronate.
  • the topical aqueous cream composition comprises moisturisers, which are biocompatible with the current invented composition and suitable for topical application.
  • moisturiser is a substance which could increase the level of moisture in the skin by filling in spaces between corneocytes of skin.
  • the moisturiser useful in the topical composition includes sodium salt of pyroglutamic acid, sodium lactate, allantoin or urea.
  • the topical aqueous cream composition comprises a base of aloe vera extract.
  • Aloe vera has long been used owing to its skin moisturising effect. Research suggests that aloe vera has wound healing attribute. Topical and oral administration of aloe vera is effective in enhancing wound healing by regulating glycosaminoglcans synthesis and promoting collagen synthesis. Aloe vera is known to have anti-inflammatory and antibacterial properties too. With respect to its biological activity, aloe vera has been used in treating eczema and psoriasis, to alleviate pruritic and xerosis symptoms.
  • the topical aqueous cream composition comprises a base of emulsifier or surfactant.
  • the emulsifier useful in the topical composition includes ceteareth-25 and ceteareth-6.
  • the topical aqueous cream composition comprises surfactant.
  • the surfactant useful in the topical composition includes Polysorbate 20, Polysorbate 40 and Polysorbate 80.
  • the compositions of current invention may also contain additional auxiliary ingredients such as diluents. Such additional auxiliary ingredients can be used to modify the rate of dissolution, viscosity, stability, osmolarity and rate of dissolution.
  • the composition of active ingredients within the scope of invention are stable in the topical preparation and as well as on skin.
  • topical compositions according to the present invention are also effective in relieving symptoms of eczema and psoriasis, such as erythema, pruritus, bumpiness, swelling, scratches, scaly and xerosis of skin.
  • the topical compositions according to the present invention are also found to be essential effective in promoting wound healing and preventing wound formation caused by eczema or psoriasis.
  • Vitamin E and carotenoids derived from red palm olein has been proven to exhibit antimicrobial activity.
  • the formulated compositions are effective in preventing the complication of eczema or psoriasis caused by microbial infection from, including, but not limited to, staphylococcal, streptococcal or Malassezia yeasts.
  • the topical compositions described herein exhibit anti-inflammatory, anti-microbial, anti-pruritic, wound healing and skin hydration attributes.
  • Preferred embodiments of the invention are illustrated in the following examples.
  • Example 1 showed the advantages of nanonization compared to conventional preparations.
  • nanonized formulation Compared to micronized formulation and non-processed formulation (raw oil), nanonized formulation showed superior oil-water combination stability that could last non- separated for approximately 24 months, stored at or below room temperature. As nanonized formulation has markedly reduced average particle size compared to micronized formulation and non-processed formulation (raw oil), nanonized formulation showed better penetration (in volume and time taken) into collagen (denatured). Nanonized formulation also inhibits growth of S. aureus, a bacteria long associated with atopic dermatitis and eczema, better compared to micronized formulation and non-processed formulation (raw oil).
  • Example 2 to 4 regarding the therapeutic effect of formulated compositions which work synergistically in alleviating symptoms of eczema and psoriasis.
  • Example 1 Example 1
  • Figure 1 illustrtated obvious penetration of nutrient into gelatin (hydrolysed collagen) in nanoformulation (observed as the dark reddish color of Vitamin E and carotenoids). No reddish color is observed in the gelatin layers treated with micronized formulation and palm oil only.
  • Figure 5 exemplified significant relief of itchiness and inflammation (redness) on a 48 years old male in the 1 st week of application with prolonged conditions of severe scratching lesions, lichenification (thickening of the skin), infected lesions (blisters, pus formation) and hyperpigmentation in old lesions.
  • Continuous application tilt daily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne de manière générale une composition thérapeutique comprenant des agents actifs nanonisés dérivés de palmier à huile et comprenant au moins un élément choisi dans le groupe A comprenant de la vitamine A et de la pro-vitamine A; au moins un élément choisi dans le groupe E comprenant de la vitamine E et de la pro-vitamine E; et au moins un élément choisi parmi un groupe C constitué de vitamine C et de pro-vitamine C. La présente invention concerne l'utilisation de ladite composition thérapeutique pour traiter ou prévenir la peau à des états secs ou prurigineux ou inflammatoires.
PCT/MY2018/050037 2017-06-22 2018-05-30 Composition dérivée de palmier à huile pour le traitement de la peau WO2018236206A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2017702335 2017-06-22
MYPI2017702335A MY196075A (en) 2017-06-22 2017-06-22 Oil Palm-Derived Composition for Skin Treatment

Publications (1)

Publication Number Publication Date
WO2018236206A1 true WO2018236206A1 (fr) 2018-12-27

Family

ID=64735857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2018/050037 WO2018236206A1 (fr) 2017-06-22 2018-05-30 Composition dérivée de palmier à huile pour le traitement de la peau

Country Status (2)

Country Link
MY (1) MY196075A (fr)
WO (1) WO2018236206A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250953A1 (en) * 2002-08-20 2005-11-10 May Choo Y Extraction of palm vitamin E, phytosterols and squalene from palm oil
US20100055187A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nanovitamin synthesis
US20100197780A1 (en) * 2007-04-23 2010-08-05 Malaysian Palm Oil Board Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith
EP2859882A1 (fr) * 2013-10-10 2015-04-15 Aulive NV Composition naturelle de soin de la peau
WO2016026527A1 (fr) * 2014-08-20 2016-02-25 Amantin Experts Compositions et procédés pour une humidification et une libération contrôlées de principes actifs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250953A1 (en) * 2002-08-20 2005-11-10 May Choo Y Extraction of palm vitamin E, phytosterols and squalene from palm oil
US20100197780A1 (en) * 2007-04-23 2010-08-05 Malaysian Palm Oil Board Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith
US20100055187A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nanovitamin synthesis
EP2859882A1 (fr) * 2013-10-10 2015-04-15 Aulive NV Composition naturelle de soin de la peau
WO2016026527A1 (fr) * 2014-08-20 2016-02-25 Amantin Experts Compositions et procédés pour une humidification et une libération contrôlées de principes actifs

Also Published As

Publication number Publication date
MY196075A (en) 2023-03-13

Similar Documents

Publication Publication Date Title
CA2534372C (fr) Vehicule pour substance moussante contenant un agent gelifiant copolymere amphiphile
US8691298B2 (en) Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care
ES2966110T3 (es) Formulaciones e instilados de cannabinoides tópicos, kits y métodos para tratar heridas tegumentarias y usos de los mismos
BRPI1004113A2 (pt) composiÇço de peràxido de benzoÍla para tratamento de pele
US20220183951A1 (en) Skin treatment methods and compositions with retinoid and delivery systems thereof
JP2007308430A (ja) ニキビ治療剤
US20210322338A1 (en) Compositions comprising cbd for treating dermatological conditions
WO2018236206A1 (fr) Composition dérivée de palmier à huile pour le traitement de la peau
EP1594456B1 (fr) Utilisation d'une composition contenant de l'oxyde de vitamine k1 ou un derive de ce dernier pour le traitement ou la prevention de lesions dermatologiques chez les mammiferes
EP4240325A1 (fr) Formulation topique comprenant des acides gras oméga-3, de la mélatonine et de la vitamine d
JP2013095717A (ja) 皮膚外用剤、水中油型エマルション組成物及びこれを含有する皮膚外用剤
JP2014144929A (ja) ビタミン類を含有するニキビの予防又は治療用組成物
US20200338019A1 (en) Topical formulations containing vitamin a and uses thereof
WO2023220273A1 (fr) Formulation topique comprenant des acides gras oméga-3, de la mélatonine et de la vitamine d
Temiz et al. Herbal Oils in Dermatology
BR102022018137A2 (pt) Composição cosmética contendo ativos da cannabis sativa l. e attalea speciosa mart ex. spreng (babaçu)
CA3079742A1 (fr) Formulations topiques contenant de la vitamine a et leurs utilisations
US20230270765A1 (en) Apothecarial compositions and related methods of treatment
JP2024516652A (ja) 過酸化ベンゾイルおよびアゼライン酸を含む外用剤およびその使用
CA3057647A1 (fr) Formulations topiques, instillations, trousses et methodes de traitement de blessures tegumentaires, et utilisations connexes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18820377

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18820377

Country of ref document: EP

Kind code of ref document: A1